[{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Shanghai Allist Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ABK3376","moa":"||EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Arrivent","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Arrivent"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Arrivent","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Hillhouse Capital Group","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Hillhouse Capital Group"},{"orgOrder":0,"company":"Arrivent","sponsor":"Sofinnova","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Sofinnova","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Sofinnova"},{"orgOrder":0,"company":"Arrivent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Inapplicable"},{"orgOrder":0,"company":"Arrivent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrivent \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Furmonertinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

AAN
Not Confirmed
AAN
Not Confirmed

Details :

Product Name : ICP-189

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 28, 2024

Lead Product(s) : ICP-189,Furmonertinib

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

02

AAN
Not Confirmed
AAN
Not Confirmed

Details : Proceeds will support NDA approval for furmonertinib, a novel oral EGFR kinase inhibitor with broad activity across EGFR mutations.

Product Name : AST2818

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

January 25, 2024

Lead Product(s) : Furmonertinib

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Goldman Sachs & Co.

Deal Size : $175.0 million

Deal Type : Public Offering

blank

03

AAN
Not Confirmed
AAN
Not Confirmed

Details : The net proceeds will be used for the clinical development of (furmonertinib), which focuses on EGFR mutant-selective tyrosine kinase inhibitors that are developed for NSCLC patients.

Product Name : AST2818

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

January 22, 2024

Lead Product(s) : Furmonertinib

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Goldman Sachs & Co.

Deal Size : $135.7 million

Deal Type : Public Offering

blank

04

AAN
Not Confirmed
AAN
Not Confirmed

Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...

Product Name : AST2818

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 30, 2023

Lead Product(s) : Furmonertinib

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

05

AAN
Not Confirmed
AAN
Not Confirmed

Details :

Product Name : ICP-189

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 13, 2023

Lead Product(s) : ICP-189,Furmonertinib

Therapeutic Area : Oncology

Highest Development Status : IND Enabling

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

06

AAN
Not Confirmed
AAN
Not Confirmed

Details :

Product Name : ICP-189

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

July 13, 2023

Lead Product(s) : ICP-189,Furmonertinib

Therapeutic Area : Oncology

Highest Development Status : IND Enabling

Sponsor : Arrivent

Deal Size : Undisclosed

Deal Type : Collaboration

blank

07

AAN
Not Confirmed
AAN
Not Confirmed

Details : The net proceedings will be used to support pivotal Phase 3 and additional studies with the Company’s lead product candidate AST2818 (furmonertinib), a highly brain penetrant, mutant-specific EGFR kinase inhibitor.

Product Name : AST2818

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

March 27, 2023

Lead Product(s) : Furmonertinib

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Sofinnova

Deal Size : $155.0 million

Deal Type : Series B Financing

blank

08

AAN
Not Confirmed
AAN
Not Confirmed

Details :

Product Name : ABK3376

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

January 03, 2023

Lead Product(s) : ABK3376,Furmonertinib

Therapeutic Area : Oncology

Highest Development Status : Preclinical

Sponsor : Shanghai Allist Pharmaceuticals

Deal Size : $187.9 million

Deal Type : Licensing Agreement

blank

09

AAN
Not Confirmed
AAN
Not Confirmed

Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...

Product Name : AST2818

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 07, 2022

Lead Product(s) : Furmonertinib

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

10

AAN
Not Confirmed
AAN
Not Confirmed

Details : Allist Pharma received approval for furmonertinib in EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) indications in China in March 2021.

Product Name : AST2818

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

June 30, 2021

Lead Product(s) : Furmonertinib

Therapeutic Area : Oncology

Highest Development Status : Approved FDF

Sponsor : Hillhouse Capital Group

Deal Size : $150.0 million

Deal Type : Series A Financing

blank